New urine test could spot kidney danger in ICU patients early
NCT ID NCT06652100
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study involves 800 adults in intensive care who provide urine samples to test a new lab test called ProNephro AKI (NGAL). The goal is to find the right cutoff value that best identifies patients at risk for moderate to severe acute kidney injury within 48-72 hours. The test measures a protein in urine that rises when kidneys are stressed. If the cutoff is established, it could help doctors act faster to protect kidney function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ProNephro AKI (NGAL) urine test
What this could lead to
If successful, this could give doctors a reliable urine test to quickly identify ICU patients at high risk for serious kidney injury, allowing earlier intervention.
What could go wrong
This is an observational study to establish a cutoff value, not a treatment trial. The test may not prove accurate enough in all patient groups, and results may not change outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Columbia University
New York, New York, 10032, United States
-
Johns Hopkins University
Baltimore, Maryland, 21224, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
The University of Alabama
Birmingham, Alabama, 35233, United States
-
UC Davis
Sacramento, California, 95817, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of New Mexico
Albuquerque, New Mexico, 87131, United States
-
Wake Forest University
Winston-Salem, North Carolina, 27109, United States
-
Yale University
New Haven, Connecticut, 06510, United States